GET DAILY SIGNALSSmith & Nephew (SNN) Q3 2026: Revenue Growth Accelerates to 3.4% Despite Guidance Trim
Key Takeaways
- Smith & Nephew reported third quarter 2026 revenue of $1.551 billion, up 3.4% year over year on both a reported and underlying basis, an acceleration from the second quarter.
- Management lowered full-year 2026 guidance, now expecting underlying revenue growth of around 3% (previously around 4%) and trading profit of roughly $1.25 billion (previously around $1.3 billion).
- Sports Medicine & ENT (Ear, Nose and Throat) was the standout, growing 8.0% to $507 million, with Sports Medicine Joint Repair up 11.1% for a fourth consecutive quarter of double-digit growth.
- US Orthopaedics remained the weak spot, with US Knee Implants down 7.3% and US Hip Implants down 1.0%, offsetting international and robotics-driven strength.
- The company confirmed that discussions with Johnson & Johnson over a potential combination with its DePuy Synthes orthopaedics business have ended, though it continues to review strategic options for the unit.
- Its $500 million share buyback remains on track, with $250 million completed through the end of the third quarter.
Why This Update Stands Out
Smith & Nephew's third quarter update carries particular weight because it tests the company's ability to sustain momentum in fast-growing businesses while stabilizing its larger US orthopaedics franchise. Through the first half of 2026, investors rewarded strong Sports Medicine and Advanced Wound Management performance but remained cautious about softness in US hip and knee reconstruction. This update also resolved months of market speculation: the company confirmed it had approached Johnson & Johnson earlier in the year about a possible combination with its DePuy Synthes orthopaedics division, only for those talks to end. With growth accelerating but guidance reduced, the report sharpened the debate over whether Smith & Nephew's innovation pipeline can offset near-term headwinds. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quarterly Results in Detail
Smith & Nephew reported third quarter 2026 revenue of $1.551 billion, up 3.4% from $1.501 billion a year earlier, with growth identical on a reported and underlying basis. The result represented an acceleration from the 1.6% underlying growth recorded in the second quarter.
By business unit, Sports Medicine & ENT grew 8.0% to $507 million, led by an 11.1% increase in Sports Medicine Joint Repair to $283 million and a 7.7% rise in Arthroscopic Enabling Technologies. Advanced Wound Management was broadly flat at $454 million, as a 10.7% increase in Advanced Wound Devices was offset by an 8.7% decline in Advanced Wound Bioactives, reflecting continued pressure from US reimbursement changes for skin substitutes. Orthopaedics returned to growth at $590 million, up 2.3%, with Other Reconstruction surging 43.8% on strong robotics-assisted CORI system placements.
However, US reconstruction remained under pressure, with US Knee Implants down 7.3% and US Hip Implants down 1.0%. Citing the outlook for US hips and knees in the fourth quarter, the company cut its full-year guidance: underlying revenue growth is now expected around 3% (previously around 4%), trading profit around $1.25 billion (previously around $1.3 billion), and free cash flow around $750 million (previously around $800 million).
Market Reaction
The market's initial reaction was measured but positive. Smith & Nephew shares rose in premarket trading following the update, with investors appearing to focus on the improving growth trajectory, resilient cash generation, and a deeper 2027 product pipeline rather than the guidance reduction. The confirmation that Johnson & Johnson discussions had ended removed a layer of uncertainty, though it also disappointed some investors who had hoped for a value-unlocking transaction in orthopaedics. Sentiment remains divided: bulls point to double-digit growth in Sports Medicine Joint Repair and the recovery in international orthopaedics, while bears emphasize persistent US knee and hip softness and the lower profit outlook heading into year-end.
Looking Ahead
Looking ahead, investors should focus on whether Smith & Nephew's new product cycle can reverse its US orthopaedics weakness. The company received FDA clearance for the cementless version of its LANDMARK knee system during the quarter, addressing a major portfolio gap as the market shifts toward cementless knees. A cemented LANDMARK version is expected in the second quarter of 2027.
Several additional catalysts are scheduled for 2027, including the CORI Hip robotic launch in the first quarter and the CORI Hip Impactor later in the year. In Advanced Wound Management, the key question is how quickly the skin substitute market normalizes following the reimbursement reset that began in 2026.
Strategic developments also remain in focus. Management said it continues to evaluate the full range of options for its Orthopaedics business after the Johnson & Johnson talks ended. Meanwhile, capital returns stay active, with the $500 million buyback halfway complete. Together, these factors mean the stock's near-term narrative will hinge on execution in US reconstruction and the pacing of its 2027 product launches, rather than any single quarterly print. From what I see, this makes the coming quarters especially important to monitor.
Exploring AI Tools in My Research
One tool I turn to regularly for spotting patterns in names like this is Tickeron’s AI Pattern Search Engine. It helps surface comparable setups across healthcare stocks and highlights technical signals that align with the fundamentals I'm tracking, giving me another layer of confirmation before forming a view on positioning.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SNN in +1.03% Uptrend, growing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SNN advanced for three days, in 191 of 331 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on SNN as a result. In 43 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
SNN moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SNN crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
The Aroon Indicator entered an Uptrend today. In 111 of 202 cases where SNN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for SNN moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 17 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 67 cases where SNN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
SNN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. SNN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.517) is normal, around the industry mean (4.142). P/E Ratio (20.991) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.035) is also within normal values, averaging (11.253). Dividend Yield (0.038) settles around the average of (0.011) among similar stocks. P/S Ratio (1.905) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medical technology devices
Industry MedicalNursingServices